Revolution Medicines
- Business
Revolution Medicines: Clinical Data Drives Valuation Shifts
New Phase 3 data for daraxonrasib recalibrates RVMD analyst ratings 2026 as Revolution Medicines pivots toward commercialization.
- Health
Daraxonrasib Phase 3 Results: PDAC Survival Gains
The RASolute 302 trial data on daraxonrasib Phase 3 results reveals a significant breakthrough in metastatic PDAC survival rates.
